Inside informationEnglish
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- DBV Technologies
- Filed
- 03/06/2026, 01:40
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 115543_20260602